1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Novel-Mechanism Antibacterials And Microbiome-Friendly Agents Now Key For Summit Therapeutics

 
• By John Davis

Rare genetic disorders are no longer in the clinical development mix at Summit, which is hunkering down on identifying novel mechanisms of action for new antibacterials, including the discovery of much-needed agents for gonorrhea and microbiome-friendly agents for gut infections.

Gonorhoeae
A novel-mechanism agent for gonorrhea has been identified by Summit Therapeutics • Source: Shutterstock

Summit Therapeutics PLC is trying to put the mid-clinical stage failure of ezutromid behind it, vowing to develop "new mechanism antibiotics to become the new standards of care".

The UK biotech is developing preclinical candidates to address the yawning lack of new therapies for gonorrhea and is bulking up its anti-infectives pipeline which already includes the Phase III-ready ridinilazole for the treatment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.